Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date: Wednesday, January 13, 2016
Time: 11:30 am PT
Location: Elizabethan Room B, Westin St. Francis Hotel, San Francisco
Live webcast: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20196
The webcast and replay of the presentation will also be accessible under the “Investors/Events” section of the website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
[email protected]
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
[email protected]
[email protected]
212-845-4271
